Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up

MeSH terms

• Adult
• Aged
• Antibodies, Monoclonal / therapeutic use*
• Antibodies, Monoclonal, Murine-Derived
• Female
• Follow-Up Studies
• Humans
• Immunologic Factors / therapeutic use*
• Leukemia, Hairy Cell / drug therapy*
• Male
• Middle Aged
• Neoplasm, Residual / drug therapy*
• Rituximab
• Treatment Outcome